Clinical Edge Journal Scan

Real-World Prevalence and Clinical Characteristics of Difficult-To-Treat PsA


 

Key clinical point: This real-world study showed that almost 1 in 6 patients with psoriatic arthritis (PsA) had potentially difficult-to-treat (D2T) disease, which was associated with extensive psoriasis, higher body mass index (BMI), and a history of inflammatory bowel disease (IBD).

Major finding: Of 467 patients, 16.5% had D2T PsA. Compared to non-D2T patients, those with D2T disease were more likely to have extensive psoriasis at diagnosis (odds ratio [OR] 5.05; P < .0001), higher BMI (OR 1.07; P = .023), and a history of IBD (OR 1.22; P = .026).

Study details: This study analyzed 467 patients with PsA from a Greek registry who had 6-months of disease duration, progressed on disease modifying anti-rheumatic drugs with different mechanisms of actions, and had disease activity index for PsA > 14 or were not at minimal disease activity .

Disclosures: The registry was funded by the Greek (Hellenic) Rheumatology Society. The authors declared no conflicts of interest.

Source: Vassilakis KD, Papagoras C, Fytanidis N, et al. Identification and characteristics of patients with potential difficult-to-treat Psoriatic Arthritis: Exploratory analyses of the Greek PsA registry . Rheumatology (Oxford). 2024 (May 17) . doi: 10.1093/rheumatology/keae263 Source

Recommended Reading

Hematological Indices Plus Ultrasound Can Detect Entheses in Patients With Psoriatic Arthritis
MDedge Rheumatology
Specialists Are ‘Underwater’ With Some Insurance-Preferred Biosimilars
MDedge Rheumatology
Recent Evidence for Home Phototherapy Benefits May Improve Access for Patients with Psoriasis
MDedge Rheumatology
Cortisol Test Confirms HPA Axis Recovery from Steroid Use
MDedge Rheumatology
Commentary: Transition from Psoriasis to PsA and New Drug Analyses, June 2024
MDedge Rheumatology
Study Finds Mace Risk Remains High in Patients with Psoriasis, Dyslipidemia
MDedge Rheumatology
Over-the-Counter Arthritis Supplements Pose Adrenal Danger
MDedge Rheumatology
Clear Coverage Preference for Humira Over Biosimilars Seen in Most Medicare Part D Plans
MDedge Rheumatology
EULAR 2024 Preview: Therapeutics in Development Take Center Stage
MDedge Rheumatology
Low Stress Resilience in Adolescence Raises Risk for Psoriatic Arthritis
MDedge Rheumatology